Please find attached monitoring agency report for the quarter ended on June 30, 2025
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mankind Pharma has submitted the monitoring agency report from CARE Ratings on the use of Rs. 3,000 crore raised through a Qualified Institutional Placement (QIP) in December 2024. The QIP proceeds were earmarked for three purposes: repayment of Commercial Paper Series I (Rs. 2,900 crore), general corporate purposes (Rs. 55 crore), and issue expenses (Rs. 45 crore). As of June 30, 2025, Rs. 2,900.03 crore has been used to repay commercial paper and the full Rs. 55 crore for general corporate purposes has been deployed. Issue expenses stand at Rs. 44.97 crore utilized out of Rs. 45 crore, with Rs. 2.43 crore deployed during the quarter. The monitoring agency confirmed no deviation from stated objects, no change in means of finance, and no unutilized proceeds remaining.
This is a routine regulatory compliance filing confirming the QIP funds have been fully deployed as planned with no deviations. Neutral to slightly positive for shareholders, as the commercial paper repayment reduces short-term debt and the clean report signals good governance and disciplined capital use.